GenSight Biologics S.A. (SIGHT.PA)
EUR 0.29
(-3.52%)
EUR 0.29
(-3.52%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -21.73 Million EUR | -7.24% |
| 2022 | -26.44 Million EUR | 1.44% |
| 2021 | -26.83 Million EUR | -11.74% |
| 2020 | -34.13 Million EUR | 18.14% |
| 2019 | -29.31 Million EUR | 10.38% |
| 2018 | -32.73 Million EUR | -37.46% |
| 2017 | -23.76 Million EUR | -9.27% |
| 2016 | -24.8 Million EUR | -60.64% |
| 2015 | -16.38 Million EUR | -106.12% |
| 2014 | -6.48 Million EUR | -128.98% |
| 2013 | -3.63 Million EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -3.67 Million EUR | 36.18% |
| 2024 Q2 | -3.67 Million EUR | 0.0% |
| 2023 Q3 | -5.75 Million EUR | 67.62% |
| 2023 Q1 | -8.4 Million EUR | -9.99% |
| 2023 Q4 | -5.75 Million EUR | 0.0% |
| 2023 FY | - EUR | -7.24% |
| 2023 Q2 | -17.76 Million EUR | -111.48% |
| 2022 Q4 | -7.63 Million EUR | 0.0% |
| 2022 Q3 | -7.63 Million EUR | 40.13% |
| 2022 Q1 | -5.75 Million EUR | 45.1% |
| 2022 Q2 | -12.75 Million EUR | -121.83% |
| 2022 FY | - EUR | 1.44% |
| 2021 FY | - EUR | -11.74% |
| 2021 Q2 | -7.6 Million EUR | -143.19% |
| 2021 Q4 | -10.47 Million EUR | 0.0% |
| 2021 Q1 | -3.12 Million EUR | 72.44% |
| 2021 Q3 | -10.47 Million EUR | -37.77% |
| 2020 Q2 | -15.71 Million EUR | -139.25% |
| 2020 Q3 | -5.43 Million EUR | 65.4% |
| 2020 Q4 | -11.34 Million EUR | -108.61% |
| 2020 FY | - EUR | 18.14% |
| 2020 Q1 | -6.56 Million EUR | 54.55% |
| 2019 Q3 | -6.35 Million EUR | 66.69% |
| 2019 Q2 | -19.07 Million EUR | -129.71% |
| 2019 Q1 | -8.3 Million EUR | 65.24% |
| 2019 FY | - EUR | 10.38% |
| 2019 Q4 | -14.44 Million EUR | -127.42% |
| 2018 Q1 | -5.58 Million EUR | 19.02% |
| 2018 Q3 | -10.78 Million EUR | 18.24% |
| 2018 Q4 | -23.88 Million EUR | -121.51% |
| 2018 FY | - EUR | -37.46% |
| 2018 Q2 | -13.19 Million EUR | -136.3% |
| 2017 Q4 | -6.89 Million EUR | 0.0% |
| 2017 Q1 | -4.99 Million EUR | 20.75% |
| 2017 FY | - EUR | -9.27% |
| 2017 Q2 | -4.99 Million EUR | 0.0% |
| 2017 Q3 | -6.89 Million EUR | -38.12% |
| 2016 Q1 | -4.61 Million EUR | -50.24% |
| 2016 Q3 | -6.29 Million EUR | -36.56% |
| 2016 Q2 | -4.61 Million EUR | 0.0% |
| 2016 Q4 | -6.29 Million EUR | 0.0% |
| 2016 FY | - EUR | -60.64% |
| 2015 Q3 | -2.96 Million EUR | -29.52% |
| 2015 Q4 | -3.06 Million EUR | -3.37% |
| 2015 FY | - EUR | -106.12% |
| 2015 Q2 | -2.29 Million EUR | 0.0% |
| 2015 Q1 | -2.29 Million EUR | -13.47% |
| 2014 Q4 | -2.02 Million EUR | 0.0% |
| 2014 FY | - EUR | -128.98% |
| 2014 Q1 | -1.22 Million EUR | 0.0% |
| 2014 Q3 | -2.02 Million EUR | -65.08% |
| 2014 Q2 | -1.22 Million EUR | -0.0% |
| 2013 FY | - EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.29 Million EUR | -560.486% |
| ABIVAX Société Anonyme | -133.2 Million EUR | 83.687% |
| Adocia SA | -22.73 Million EUR | 4.408% |
| Aelis Farma SA | -6.34 Million EUR | -242.366% |
| Biophytis S.A. | -13.8 Million EUR | -57.418% |
| Advicenne S.A. | -6.24 Million EUR | -248.014% |
| genOway Société anonyme | 6.35 Million EUR | 442.164% |
| IntegraGen SA | -52.5 Thousand EUR | -41288.111% |
| Medesis Pharma S.A. | -3.84 Million EUR | -465.167% |
| Neovacs S.A. | -8.44 Million EUR | -157.174% |
| NFL Biosciences SA | -4.04 Million EUR | -436.636% |
| Plant Advanced Technologies SA | 72.53 Thousand EUR | 30060.017% |
| Quantum Genomics Société Anonyme | -2.87 Million EUR | -656.226% |
| Sensorion SA | -22.31 Million EUR | 2.616% |
| Theranexus Société Anonyme | -7.38 Million EUR | -194.156% |
| TME Pharma N.V. | -5.07 Million EUR | -328.431% |
| Valbiotis SA | -6.95 Million EUR | -212.437% |
| TheraVet SA | -517.33 Thousand EUR | -4100.365% |
| Valerio Therapeutics Société anonyme | -18.91 Million EUR | -14.876% |
| argenx SE | -199.5 Million EUR | 89.108% |
| BioSenic S.A. | -6.79 Million EUR | -219.747% |
| Celyad Oncology SA | -7.76 Million EUR | -179.918% |
| DBV Technologies S.A. | -79.53 Million EUR | 72.677% |
| Galapagos NV | 51.03 Million EUR | 142.577% |
| Genfit S.A. | -28.05 Million EUR | 22.534% |
| GeNeuro SA | -14.31 Million EUR | -51.77% |
| Hyloris Pharmaceuticals SA | -14.98 Million EUR | -45.06% |
| Innate Pharma S.A. | -7.57 Million EUR | -186.751% |
| Inventiva S.A. | -101.84 Million EUR | 78.664% |
| MaaT Pharma SA | -19.74 Million EUR | -10.081% |
| MedinCell S.A. | -20.04 Million EUR | -8.401% |
| Nanobiotix S.A. | -34.01 Million EUR | 36.124% |
| Onward Medical N.V. | -35.23 Million EUR | 38.327% |
| Oryzon Genomics S.A. | -4.43 Million EUR | -390.148% |
| OSE Immunotherapeutics SA | -23.26 Million EUR | 6.602% |
| Oxurion NV | -16.72 Million EUR | -29.894% |
| Pharming Group N.V. | 4.98 Million EUR | 536.261% |
| Poxel S.A. | -12.17 Million EUR | -78.422% |
| Transgene SA | -27.02 Million EUR | 19.59% |
| Financière de Tubize SA | 184.57 Thousand EUR | 11873.247% |
| UCB SA | 1.26 Billion EUR | 101.712% |
| Valneva SE | -64.51 Million EUR | 66.319% |
| Vivoryon Therapeutics N.V. | -28.35 Million EUR | 23.359% |